Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Overview of attention for article published in Drug Design, Development and Therapy, January 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 9 publications that cite this research output.

9

The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.

Frequency of Complete Remission With R-CHOP Therapy in Patients With Diffuse Large B Cell Lymphoma

Article in Cureus (April 2024)

Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell lymphoma

Article in Journal of Pathology and Translational Medicine (January 2024)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Article in Experimental Hematology & Oncology (August 2023)